Physician Continuing Medical Education
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Strategic Consultants International. Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
This educational activity for 1 contact hour is provided by Postgraduate Institute for Medicine.
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you within three weeks.
DISCLOSURE of Interest
The Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.
Statement of Need
Therapeutic drug monitoring and pharmacokinetic/pharmacodynamics guided dosing is an important concept in optimal management of patients with inflammatory bowel disease. Assessment of TPMT levels can help guide use of azathioprine, and data are emerging on the role of using metabolites to guide dosing and identify patients at risk of adverse events. In addition, trough levels of anti-TNF levels can guide treatment planning for patients receiving anti-TNF, and for secondary non-responders there is increasing interest in the role of anti-drug antibodies. These concepts are rapidly evolving, but many require careful consideration and, if used in the clinic, should be used as part of a wider consideration which includes clinical assessment, standard laboratory data, and patient informed choice.